“This is part of our commitment to delivering Smarter AI for All—developing and deploying technology that can empower ...

In the last two years, two drugs have been federally approved to slow the onset of Alzheimer's disease in its early stages, ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) ...

University College London (UCL) has selected Mace, a global construction company, to build its neuroscience facility at 256 ...

Sibstar, the UK’s leading debit card and app for people living with dementia, has today announced the appointment of GoHenry ...

In people with mild cognitive impairment, galantamine, compared to placebo, may make little to no difference in improving memory or the ability to do self-care activities. However, participants who ...

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, ...

The global neuromodulation device market will be worth $11.4bn by 2033, as per a market model from GlobalData.

AMP Robotics Corp. ("AMP"), a leading provider of artificial intelligence (AI)-powered sortation at scale for the waste and recycling ... today announced that it will host its annual Innovation Day, a ...

Older adults with calcium and magnesium deficiencies also had poorer cognitive performance compared to peers with adequate micronutrient levels, a recent study has found.